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Abstract
Background:  One year after the adoption of artesunate-amodiaquine (AS/AQ) as first-line
therapy for the treatment of uncomplicated malaria, this study was designed to assess the
treatment practices regarding anti-malarial drugs at health facilities in four rural areas in southern
Cameroon.
Methods: Between April and August 2005, information was collected by interviewing fifty-two
health professionals from twelve rural health facilities, using a structured questionnaire.
Results: In 2005, only three anti-malarial drugs were used in rural health facilities, including:
amodiaquine, quinine and sulphadoxine-pyrimethamine. Only 2.0% of the health professionals
prescribed the recommended AS/AQ combination. After reading the treatment guidelines, 75.0%
were in favour of the treatment protocol with the following limitations: lack of paediatric
formulations, high cost and large number of tablets per day. Up to 21.0% of professionals did not
prescribe AS/AQ because of the level of adverse events attributed to the use of amodiaquine as
monotherapy.
Conclusion: The present study indicates that AS/AQ was not available in the public health facilities
at the time of the study, and health practitioners were not informed about the new treatment
guidelines. Results of qualitative analysis suggest that prescribers should be involved as soon as
possible in projects related to the optimization of treatment guidelines and comply with new drugs.
Adapted formulations should be made available at the international level and implemented locally
before new drugs and treatments are proposed through a national control programme. This
baseline information will be useful to monitor progresses in the implementation of artemisinin-
based combination therapy in Cameroon.
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Background
Implementation of new drug policies is a complex issue,
especially in poor rural areas where nurses are used to pre-
scribe well-known drugs, readily available, inexpensive
and easy to administer [1]. Few studies have investigated
the adherence of medical practitioners to drug policy
changes and new treatment protocols based on the use of
artemisinin-based combination therapy (ACT). This work
was carried out in two parts. In a previous study, the avail-
ability of anti-malarial drugs, treatment practices and
acceptability of the new protocol by health professionals,
have been assessed in urban health facilities in Yaoundé,
capital city of Cameroon [2]. The present study analyses
attitudes and practices of medical doctors and nurses
regarding the treatment of malaria in rural health facilities
in southern Cameroon. Specific objectives describe spe-
cific prescription patterns of anti-malarial drugs to adults,
pregnant women and under five children, including atti-
tudes and perception towards the new treatment guide-
lines based on ACT.
Methods
Setting
The survey was conducted form April to August 2005, in
twelve rural health facilities (one district hospital and
eleven health centres) from Kribi, Mengong, Nkoemvone
and Ngoazip, located in the southern province of Cam-
eroon. In this part of Cameroon, located in the rainy
equatorial forest, the transmission of malaria is perennial
and Plasmodium falciparum infection accounts for 95% of
malaria cases.
Study population
Fifty two health professionals (n = 52) were selected
including eight medical doctors (15.4%), thirty four
nurses (65.4%), and ten health assistants (19.2%). Of
these health professionals, 57.7% belonged to public
health facilities, 26.9% worked in confessional health
centres and 15.4% in private clinics.
Data collection
Lists of anti-malarial drugs available in public, private
health facilities and drugstores were established in each
site. Knowledge, attitudes and practices of medical practi-
tioners were collected using a structured questionnaire,
previously designed and implemented in two health cen-
tres. The questionnaire was divided into four sections
including i) evaluation of knowledge and attitudes of
medical practitioners regarding treatment guidelines; ii)
current use and regimen of anti-malarial drugs as first-line
and second-line therapies; iii) knowledge and use of
artemisinin derivatives and ACT and iv) sources of infor-
mation on malaria and anti-malarial drugs.
Data analysis
Responses from interviews were numerically coded and
analysed using Epi-Info version 6.04. Drug costs are
expressed in US$. Differences in proportion were analysed
using chi-square test when appropriate and significance
was set at p < 0.05. This protocol was approved by the
operational research board of the Ministry of Public
Health, in Cameroon.
Results
Availability of anti-malarial drugs and treatment cost
According to the local drug management office, fourteen
anti-malarial drugs were available, all of which being
generics (Table 1). Three of these drugs, i.e. amodiaquine,
quinine and sulphadoxine-pyrimethamine, were used in
rural health facilities. Most anti-malarial drugs available
in private health structures were trade-named although an
agreement has been signed between the national drug
office (CENAME) and the private sector. Health profes-
sionals usually mentioned the following four trade-
named anti-malarial drugs: artemether/lumefantrine
(Coartem®), dihydroartemisinin (Cotecxin®), artesunate
(Plasmotrim®) and amodiaquine (Camoquin®). Chloro-
quine remained available mainly in confessional health
facilities. Public health centres provided the cheapest
drugs (p < 0.05). The only AS/AQ available was the blister
combination trade-named Arsucam®.
New protocol guidelines knowledge by medical 
practitioners
Four (7.7%) of the fifty two interviewed health profes-
sionals knew that AS/AQ was the recommended drug,
mentioned in the new guidelines for the treatment of
uncomplicated malaria in Cameroon (one was able to
provide the official document). According to 92.3% of the
medical practitioners, amodiaquine remained the recom-
mended drug. Such recommendation was based upon a
national consensus meeting held in February 2004 pro-
posing the use of amodiaquine alone up to availability of
AS/AQ by CENAME.
Adherence to treatment guidelines
After being informed about the new treatment guidelines
and about the drugs recommended by the national proto-
col, thirty-nine health professionals (75.0%) were in
favour of the new treatment guidelines and were disposed
to prescribe AS/AQ combination if available. Among the
remaining practitioners (n = 13), eleven (21.0%) declined
to accept treatment guidelines based on the presumed
adverse events attributed to amodiaquine when used in
monotherapy (mainly asthenia or/and vomiting). Qui-
nine or artesunate alone was prescribed by 4.0% of the
practitionners.Malaria Journal 2009, 8:174 http://www.malariajournal.com/content/8/1/174
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Attitudes related to AS/AQ combination therapy
With regards to AS/AQ combination therapy, nineteen of
the fifty two health professionals (36.5%) complained
about the lack of paediatric forms (suppositories and oral
solutions) which was considered as a crucial problem for
children's prescription. 34.6% thought that, drugs with an
estimated price of 7.5 US$ were too expensive for poor
rural patients. 26.9% of the practitioners suggested a
reduction in the number of artesunate and amodiaquine
tablets per dose while 25.0% argued for a reduction of the
dosage of amodiaquine alone. 19.2% mentioned a lack of
information related to the use of ACT in the protocol
guidelines; 5.8% indicated that the choice of white colour
(for artesunate tablets) and yellow colour (for amodi-
aquine tablets) was not wise, as it was difficult to differen-
tiate between the two under low light. 5.8% complained
about the absence of pre-packaged drugs for home man-
agement of malaria and 2.0% proposed a systematic
administration of antibiotics with malaria treatment.
Anti-malarial drugs used as first-line treatment
Quinine was the most prescribed anti-malarial drug for
adult patients. Tablets (300 mg) and parenteral quinine
were respectively used by 65.3% and 7.6% of the prescrib-
ers while 71.2% preferred tablets for pregnant women
(Table 2). 2.0% of the physicians administered the recom-
mended combination therapy (AS/AQ) to adults. No
artemisinin-based combination therapy has been men-
tioned for pregnant women.
Concerning children with suspected malaria, nurses
administered oral solutions of amodiaquine (67.3%) or
quinine (23.0%). Injectable quinine was prescribed as
first-line drug by 5.7% of nurses and 2.0% declared hav-
ing prescribed the recommended AS/AQ.
Table 1: Available anti-malarial drugs and treatment costs in public, private, confessional health facilities and pharmacies
Available anti-malarial drugs Mean treatment costs (US $) in health facilities (HF) and private pharmacies
Public HF Private HF Confessional HF Pharmacies
AQ oral solution 1.45 3.45 3.27 3.63
AQ 200 mg/tablet 0.22 1.09 0.81 NA
Arsucam® (AS/AQ) NA 7.63 NA 7.36
Arsumax® (AS) NA 5.45 2.20 5.54
Artesiane® oral solution NA 5.81 NA 6.18
CQ 250 mg/tablet NA NA 0.72 NA
Cotecxin® oral solution NA 5.81 5.81 6.78
Fansidar® (SP 525 mg) 0.18 0.90 0.54 1.63
Halfan® oral solution NA 6.72 6.72 6.72
Halfan® 250 mg/tablet NA 6.36 6.18 6.32
Plasmotrim® 50 mg/rectal form NA 4.36 NA 4.45
Quinine 100 mg/100 ml 2.20 NA NA NA
Quinine 100 mg/tablet 0.90 1.81 1.45 NA
Quinine 200 mg/tablet 1.09 NA 1.63 NA
Quinine 300 mg/tablet 1.27 2.00 2.00 1.45
Injectable quinine 400 mg 3.00 5.45 4.36 NA
Injectable quinine 600 mg 2.63 5.45 6.54 NA
Injectable Quinimax® 500 mg 4.36 5.45 NA 4.54
NB: all drugs available were not prescribed and therefore, some in the tables are not mentioned in the results.
AQ: amodiaquine; AS: artesunate; CQ: chloroquine; NA: not available.
Artesiane®: artesunate; Cotecxin®: DiHydroartemisinin; Fansidar®: sulphadoxine/pyrimethamine (SP); Halfan®: halofantrine; Plasmotrim®: 
artesunate suppositories; Quinimax®: quinine.
Table 2: Drugs used as first-line treatment by health professionals in rural zone
Anti-malaria drugs Adults (%) Pregnant women (%) Children under 5 (%)
Arsucam® (AS/AQ) 2.0 0.0 2.0
Quinine tablets 65.3 71.2 23.0
Amodiaquine 21.1 15.4 67.3
Chloroquine 2.0 0.0 0.0
Injectable quinine 7.6 7.6 5.7
Sulphadoxine/Pyrimethamine 2.0 3.8 0.0
Amodiaquine+SP 0.0 2.0 0.0
Artemether (injectable) 0.0 0.0 2.0Malaria Journal 2009, 8:174 http://www.malariajournal.com/content/8/1/174
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Anti-malarial drugs used as second-line treatment
According to thirty-two prescribers (61.5%), persistent
fever occurring at day 3 post-treatment (associated or not
with other clinical signs) was the main criteria to evaluate
therapeutic failure (Table 3). In that case, 36.4% per-
formed a thick blood smear test prior to treatment using
another anti-malarial drug. 53.3% directly used injectable
quinine in adults (68.8%), pregnant women (84.4%) or
children (48.0%). Moreover, 2% prescribed antibiotics.
Although nurses tended to use more injectable drugs than
doctors, the differences in prescribing patterns were not
significant (p = 0.08).
Health professionals mentioned that severe anaemia
(78.6%) and/or signs of cerebral malaria (42.9%) were
the main observed complications usually referred to spe-
cialized hospitals.
Use of artemisinin derivatives and ACT
Twenty-one (40.4%) of the fifty two health professionals
never used artemisinin derivatives since they started work-
ing in rural health facilities (Table 4). Artemisinin deriva-
tives, including artesunate, dihydroartemisinin and
artemether, were prescribed as monotherapy (44.3%) or
as both monotherapy and bitherapy (15.3%). Artesunate
and dihydroartemisinin alone were found as the most
prescribed drugs. Artemether/lumefantrine was the first
artemisinin-based combination mentioned by prescribers
in rural district hospitals. However, this drug was not
available in drugstores and pharmacies at the time of the
study. About 62% of the prescribers did not use artemisi-
nin derivatives for various reasons: (1) non-availability of
the drugs in rural areas; (2) only partial information
(19%); (3) high cost (14.3%); (5) treatment efficacy being
suspected to be lower than the currently used quinine
(4.8%).
On the other hand, 7.7% of health professionals declared
prescribing drugs according to their trade names and 5.8%
were influenced by patient's requests (Table 5).
Main sources of malaria drugs information in rural health 
facilities
A total of eight physicians and two nurses (19.2% of the
personnel) had followed training sessions on malaria
treatments. In rural health facilities, prescribers usually
obtained information about malaria treatment and drugs
from their colleagues (40.4%) and from medical visitors
employed by private pharmaceutical providers (36.5%).
Only 5.8% had participated to a training seminar organ-
ized by the Ministry of Public Health of Cameroon within
the last two years (Table 6).
Discussion
Reporting baseline data at the time of introduction of ACT
provides useful information to highlight the strength and
weaknesses of implementation programmes, and set up
proper key progress indicators. The present survey high-
lights some of the difficulties related to the implementa-
tion of new national guidelines for the treatment of
malaria in rural areas, where drug availability is restricted
to public health facilities, religious health institutions,
and a few drugstores. Our findings are in agreement with
a previous study conducted in Zambia [3], indicating that
isolated rural areas, the most concerned by malaria preva-
lence, have difficulties to be educated about treatment
progresses and have limited access to official information.
Moreover, negative attitudes from doctors and medical
assistants toward the national guidelines were reported,
mainly based upon mild adverse events attributed to
amodiaquine (asthenia and vomiting), and rare deadly
adverse events (agranulocytosis) when previously used as
a prophylactic drug, leading to its market withdrawal for
many years. Such observations should be taken into con-
sideration, as the new 3-days regimen of AS/AQ was
implemented in 2007 in Cameroon, made of a single
daily bicoloured tablet; yellow (artesunate) and white
(amodiaquine).
The lack of impact of the national malaria treatment
guidelines on the behaviour of medical practitioner has
Table 3: Drugs used as second-line treatment by health professionals in rural zone
Anti-malarial drugs Adults (%) Pregnant women (%) Under-five children (%)
Injectable artemether 2.0 0.0 2.0
Injectable quinine 68.8 84.4 48.0
Amodiaquine 2.0 0.0 3.9
Artesunate 3.9 2.0 0.0
Dihydroartemisinin 2.0 2.0 7.6
Halofantrine 2.0 0.0 2.0
Quinine tablets 9.6 7.6 32.5
Injectable quinine+SP 2.0 0.0 0.0
Quinine + antibiotics 2.0 2.0 2.0
Sulphadoxine/pyrimethamine 5.7 2.0 2.0
SP: sulphadoxine/pyrimethamineMalaria Journal 2009, 8:174 http://www.malariajournal.com/content/8/1/174
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previously been reported in Burkina Faso [4] and Sudan
[5]. Quinine has already been referred as the most pre-
scribed first-line anti-malarial drug (84.4%) in public
health institutions in Cameroon [6]. These findings sug-
gested that ensuring the availability of AS/AQ in the pub-
lic sector will not be the only incentive to ensure proper
use and compliance to this regimen. Nationwide informa-
tion on the rational use of anti-malarial drugs must be
provided together with proper training of health profes-
sionals in order to obtain their full participation and
understanding. In addition, the current widespread avail-
ability of various artemisinin monotherapies from the pri-
vate sector and the presence of private medical
representatives from pharmaceutical companies might
influence specific prescriptions in each health facility.
Therefore, training, information and early implication of
health professionals in decision analysis should strongly
improve adherence to newly proposed guidelines for the
treatment of malaria.
At the time of the study, in August 2005, the use of AS/AQ
was not implemented in rural areas of southern Cam-
eroon despite the official publication and access to the
new guidelines in February 2004. However, for the treat-
ment of uncomplicated malaria, a majority of health pro-
fessionals will favour the present combination if
appropriately formulated (paediatric forms and reduced
pills intake) and offered at affordable price.
Modifying treatment protocols is a complex issue. The
greatest challenge is an early supply of new drugs, at low
price, provided in all health institutions preceded by the
proper information in order to convince health profes-
sionals to adhere to new clinical practices. In addition, fol-
lowing a proposal from WHO, a public release of the
Cameroonian Ministry of Public Health announced that
all anti-malarial drugs available in monotherapy should
not be sold and used anymore in health facilities. There-
fore, nationwide withdrawal of these drugs was per-
formed in public and private pharmacies and drugstores,
starting January 2007. Such a measure might prove effi-
cient if (i) the recommended AS/AQ formulation will be
made available at the national level with adapted paediat-
ric formulations and (ii) reasons why monotherapies are
not recommended anymore are clearly explained to the
overall population.
Furthermore, in February 2007, the cost of malaria treat-
ment was reduced to a price between 0.30 US$ and 1.3
US$ in public hospitals and health centres, therefore,
improving access to treatment for the rural population.
Conclusion
Prescribers should be involved as soon as possible in
projects related to the optimization of treatment guide-
lines and comply with new drugs. This baseline informa-
tion could be used as the starting points for further
monitoring and evaluation of artemisinin-based combi-
nation therapy in Cameroon.
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Table 4: Artemisinin derivatives prescribed (cited) by health 
professionals in rural zones
Artemisinin derivatives (Number) % of prescribers
Not used (n = 21) (21) 40.4
Used (n = 31)
Monotherapies
Artesunate (11) 21.2
Dihydroartemisinin (9) 17.3
Artemether (3) 5.8
Bitherapies (ACT)
Coartem® (6) 11.5
Arsucam® (2) 3.8
Table 5: Main selection criteria of artemisinin derivatives 
according to prescribers (n = 52)
Choosing criteria (Number) % of prescribers
Therapeutic efficacy (18) 34.6
Observance (few tablets) (14) 26.9
Few adverse effects (7) 13.5
Drug cost (lowest price) (6) 11.5
Name of drugs (4) 7.7
Patient's request (3) 5.8
Table 6: Main sources of information in rural health facilities
Sources of information (Number) % of prescribers
Health personnel (21) 40.4
Medical visitors (20) 36.5
Medias (5) 9.6
Medical reviews (4) 7.7
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